T2 Biosystems Announces Patent Covering T2Hemostasis

T2 Biosystems Announces Patent Covering T2Hemostasis

February 5, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)--

Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma

Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma

February 5, 2013

One of Seven Phase 2 Studies Across Three Different Acceleron Programs
Initiated in the Last Three Months

Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer

Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer

February 5, 2013

Dalantercept Now in Four Phase 2 Studies to Treat Aggressive Cancers with Limited Treatment Options

Tangent Medical Named Most Innovative Company for the 2013 Business Excellence Awards

Tangent Medical Named Most Innovative Company for the 2013 Business Excellence Awards

January 30, 2013

Medical Device Start-Up Named a Winner at National Awards Ceremony Event

ANN ARBOR, MI--(Marketwire - Jan 30, 2013) - Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, has been named the Most Innovative Company at the 2013 Business Excellence Awards announced recently by ActionCOACH, a leading business coaching firm sponsoring the award event.

Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes

Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes

January 29, 2013

Acceleron earns $10 million milestone payment from collaboration partner Celgene Corporation

T2 Biosystems Announces Issuance of Patents Covering Components of the T2Dx Direct Detection Device

T2 Biosystems Announces Issuance of Patents Covering Components of the T2Dx Direct Detection Device

January 29, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)--

LS9 Appoints Tjerk de Ruiter as President and Chief Executive Officer

LS9 Appoints Tjerk de Ruiter as President and Chief Executive Officer

January 23, 2013

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced the appointment of Tjerk de Ruiter as President and Chief Executive Officer. Mr. de Ruiter joined LS9 as Chairman of the Board in August 2012 and will maintain that position. Ed Dineen, who has served as CEO of LS9 since December 2010, will remain a member of LS9's board of directors.

Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer

Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer

January 22, 2013
Cambridge, Mass., January 22, 2013 - Selventa today announced that it is developing a powerful new class of diagnostic test that will accelerate the implementation of personalized healthcare. Systems Diagnostics, or SysDx™, will be a novel diagnostic tests that can consist of “multi-omic” biomarkersselected through a rigorous Big Data analysis of a patient’s biological profile includinggenomic, epigenomic, transcriptomic, proteomic, metabolomic and electronic medial record information.

Moderna Appoints Divakar Ramakrishnan, Ph.D., As Senior Vice President Of Process Development, Manufacturing And Quality

Moderna Appoints Divakar Ramakrishnan, Ph.D., As Senior Vice President Of Process Development, Manufacturing And Quality

January 16, 2013

CAMBRIDGE, Mass., Jan. 16, 2013 /PRNewswire/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, announced today that Divakar Ramakrishnan, Ph.D., is joining the company as Senior Vice President of Process Development, Manufacturing and Quality. His appointment is effective immediately.

BIND Granted 5 US Patents for Medicinal Nanoengineering® Platform & Lead Drug Candidate, BIND-014

BIND Granted 5 US Patents for Medicinal Nanoengineering® Platform & Lead Drug Candidate, BIND-014

January 8, 2013

Total of Ten U.S. Patents Issued to Company in 2012